Question · asked by 1 review

Azithromycin (500 mg 20 ‐ 28 days) vs meglumine antimoniate (15 ‐ 20 mg/kg/d: Complete cure, at least 3 months after the end of treatment

Population
People with American cutaneous and mucocutaneous leishmaniasis
Intervention
Azithromycin (500 mg 20 ‐ 28 days)
Comparison
meglumine antimoniate (15 ‐ 20 mg/kg/d
Outcome
Complete cure, at least 3 months after the end of treatment

Azithromycin (500 mg 20 ‐ 28 days) probably leads to lower complete cure, at least 3 months after the end of treatment compared with meglumine antimoniate (15 ‐ 20 mg/kg/d (moderate certainty).

What each review found

Current versions only
FindingEffectStudiesGRADE certainty
Azithromycin (500 mg 20 ‐ 28 days) vs meglumine antimoniate (15 ‐ 20 mg/kg/d
Complete cure, at least 3 months after the end of treatment · People with American cutaneous and mucocutaneous leishmaniasis
Azithromycin (500 mg 20 ‐ 28 days) probably leads to lower complete cure, at least 3 months after the end of treatment compared with meglumine antimoniate (15 ‐ 20 mg/kg/d (moderate certainty).
Interventions for American cutaneous and mucocutaneous leishmaniasis (2020) · Cochrane Headline outcomes only
RR 0.51 [0.34, 0.76]2 studies · 93 participantsModerate

Findings are shown side by side, never pooled across reviews.

The reviews

ReviewSearched up toIncluded studiesAMSTAR 2
Interventions for American cutaneous and mucocutaneous leishmaniasis
2020 · Cochrane Headline outcomes only
Not reportedNot extractedNot assessed
How reviews are matched to this question

Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.